Nuvation Bio
NUVB
98 hedge funds and large institutions have $1.5B invested in Nuvation Bio in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 38 increasing their positions, 22 reducing their positions, and 16 closing their positions.
73% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 22
58% more call options, than puts
Call options by funds: $396K | Put options by funds: $250K
10% more capital invested
Capital invested by funds: $1.36B → $1.5B (+$139M)
1.48% more ownership
Funds ownership: 67.99% → 69.47% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
6% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 16
1% less funds holding
Funds holding: 99 → 98 (-1)
Top Buyers
| 1 |
BlackRock
New York
|
+$19.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.31M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.49M |
| 4 |
State Street
Boston,
Massachusetts
|
+$4.37M |
| 5 |
Millennium Management
New York
|
+$3.39M |
Top Sellers
| 1 |
Franklin Resources
San Mateo,
California
|
-$7.45M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$6.86M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.69M |
| 4 |
Renaissance Technologies
New York
|
-$3.77M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$2.62M |
NUVB Hedge Fund Activity: Q3 2021 in Review
98 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Nuvation Bio (NUVB) for Q3 2021, worth a combined $1.5B — up 10% from $1.36B a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of NUVB and 15 opened new positions — a net loss of 1 holder — while 22 trimmed existing stakes and 38 added.
The largest buyer was BlackRock, adding an estimated $19.8M. The largest seller was Franklin Resources, exiting entirely with an estimated $7.45M sold.
- 98 institutional investors held Nuvation Bio (NUVB) as of Q3 2021, down from 99 in Q2 2021.
- Funds reported $1.5B of Nuvation Bio stock for Q3 2021, up 10% quarter-over-quarter.
- 15 funds opened new Nuvation Bio positions in Q3 2021 and 16 closed out, a net change of -1 holder.
- The largest Nuvation Bio buyer in Q3 2021 was BlackRock, an estimated $19.8M added.
- The largest Nuvation Bio seller in Q3 2021 was Franklin Resources, an estimated $7.45M sold.
Based on aggregated 13F filings for Q3 2021.